These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations). Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697 [TBL] [Abstract][Full Text] [Related]
5. Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias. Krol RB; Saksena S; Prakash A Curr Cardiol Rep; 1999 Nov; 1(4):282-8. PubMed ID: 10980855 [TBL] [Abstract][Full Text] [Related]
6. Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators. Van Herendael H; Pinter A; Ahmad K; Korley V; Mangat I; Dorian P Europace; 2010 May; 12(5):618-25. PubMed ID: 20304841 [TBL] [Abstract][Full Text] [Related]
7. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators N Engl J Med; 1997 Nov; 337(22):1576-83. PubMed ID: 9411221 [TBL] [Abstract][Full Text] [Related]
8. Current role of the automatic implantable cardioverter-defibrillator in the treatment of life-threatening ventricular arrhythmias. Kay GN; Plumb VJ; Dailey SM; Epstein AE Am J Med; 1990 Jan; 88(1N):25N-34N. PubMed ID: 2195882 [TBL] [Abstract][Full Text] [Related]
9. Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Greene HL Am J Cardiol; 1996 Aug; 78(4A):61-6. PubMed ID: 8780330 [TBL] [Abstract][Full Text] [Related]
11. Drug and defibrillator interactions. Carnes CA; Mehdirad AA; Nelson SD Pharmacotherapy; 1998; 18(3):516-25. PubMed ID: 9620103 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH; Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672 [TBL] [Abstract][Full Text] [Related]
14. Third- and fourth-generation implantable cardioverter defibrillators: current status and future development. Saksena S; Diaz ML; Varanasi S; Mathew P; Berg J; Krol RB; Kaushik RR J Interv Cardiol; 1994 Oct; 7(5):427-40. PubMed ID: 10155192 [TBL] [Abstract][Full Text] [Related]
15. Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. Page RL Am J Cardiol; 2000 Jun; 85(12):1481-5. PubMed ID: 10856397 [No Abstract] [Full Text] [Related]
16. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. Ho AT; Pai SM; Timothy P; Pai RG Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799 [TBL] [Abstract][Full Text] [Related]
17. High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. Link MS; Costeas XF; Griffith JL; Colburn CD; Estes NA; Wang PJ J Am Coll Cardiol; 1997 Feb; 29(2):370-5. PubMed ID: 9014991 [TBL] [Abstract][Full Text] [Related]
18. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882 [TBL] [Abstract][Full Text] [Related]
19. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review. Hilleman DE; Bauman AL Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745 [TBL] [Abstract][Full Text] [Related]
20. A benefit-risk assessment of class III antiarrhythmic agents. Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]